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Abstract
Neuropathic pain is caused by a lesion or disease of the somatosensory system, including 
peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7–10% of the general 
population. Multiple causes of neuropathic pain have been described and its incidence is likely to 
increase owing to the ageing global population, increased incidence of diabetes mellitus and 
improved survival from cancer after chemotherapy. Indeed, imbalances between excitatory and 
inhibitory somatosensory signalling, alterations in ion channels and variability in the way that pain 
messages are modulated in the central nervous system all have been implicated in neuropathic 
pain. The burden of chronic neuropathic pain seems to be related to the complexity of neuropathic 
symptoms, poor outcomes and difficult treatment decisions. Importantly, quality of life is impaired 
in patients with neuropathic pain owing to increased drug prescriptions and visits to health care 
providers, as well as the morbidity from the pain itself and the inciting disease. Despite challenges, 
progress in the understanding of the pathophysiology of neuropathic pain is spurring the 
development of new diagnostic procedures and personalized interventions, which emphasize the 
need for a multidisciplinary approach to the management of neuropathic pain.
Although distinct definitions of neuropathic pain have been used over the years, its most 
recent (2011) and widely accepted definition is pain caused by a lesion or disease of the 
somatosensory system. The somatosensory system allows for the perception of touch, 
pressure, pain, temperature, position, movement and vibration. The somatosensory nerves 
arise in the skin, muscles, joints and fascia and include thermoreceptors, mechanoreceptors, 
chemoreceptors, pruriceptors and nociceptors that send signals to the spinal cord and 
eventually to the brain for further processing (BOX 1); most sensory processes involve a 
thalamic nucleus receiving a sensory signal that is then directed to the cerebral cortex. 
Lesions or diseases of the somatosensory nervous system can lead to altered and disordered 
transmission of sensory signals into the spinal cord and the brain; common conditions 
associated with neuropathic pain include postherpetic neuralgia, trigeminal neuralgia, 
painful radiculopathy, diabetic neuropathy, HIV infection, leprosy, amputation, peripheral 
nerve injury pain and stroke (in the form of central post-stroke pain) (FIG. 1). Not all 
patients with peripheral neuropathy or central nervous injury develop neuropathic pain; for 
example, a large cohort study of patients with diabetes mellitus indicated that the overall 
prevalence of neuropathic pain symptoms was 21% in patients with clinical neuropathy. 
However, the prevalence of neuropathic pain increased to 60% in those with severe clinical 
neuropathy1. Importantly, neuropathic pain is mechanistically dissimilar to other chronic 
pain conditions such as inflammatory pain that occurs, for example, in rheumatoid arthritis, 
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in which the primary cause is inflammation with altered chemical events at the site of 
inflammation; such pain is diagnosed and treated differently2.
Neuropathic pain is associated with increased drug prescriptions and visits to health care 
providers3,4. Patients typically experience a distinct set of symptoms, such as burning and 
electrical-like sensations, and pain resulting from non-painful stimulations (such as light 
touching); the symptoms persist and have a tendency to become chronic and respond less to 
pain medications. Sleep disturbances, anxiety and depression are frequent and severe in 
patients with neuropathic pain, and quality of life is more impaired in patients with chronic 
neuropathic pain than in those with chronic non-neuropathic pain that does not come from 
damaged or irritated nerves3,5.
Despite the increases of placebo responses6,7 that result in the failure of multiple new drugs 
in clinical trials, recent progress in our understanding of the pathophysiology of neuropathic 
pain provides optimism for the development of new diagnostic procedures and personalized 
interventions. This Primer presents the current descriptions of the presentation, causes, 
diagnosis and treatment of neuropathic pain, with a focus on peripheral neuropathic pain 
given that our knowledge is greater than that of central neuropathic pain.
Epidemiology
The estimation of the incidence and prevalence of neuropathic pain has been difficult 
because of the lack of simple diagnostic criteria for large epidemiological surveys in the 
general population. Thus, the prevalence of neuropathic pain in the chronic pain population 
has mainly been estimated on the basis of studies8 conducted by specialized centres with a 
focus on specific conditions, such as postherpetic neuralgia9, 10, painful diabetic 
polyneuropathy1,11–13, postsurgery neuropathic pain14, multiple sclerosis15, 16, spinal cord 
injury17, stroke18 and cancer19, 20.
The recent development of simple screening tools in the form of questionnaires21 has helped 
conduct several large epidemiological surveys in different countries (the United Kingdom, 
the United States, France and Brazil) and provided valuable new information on the general 
prevalence of neuropathic pain4. In using screening tools, such as the Douleur 
Neuropathique 4 questions (DN4)22 or the Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS) pain scale23 (BOX 2), the prevalence of chronic pain with neuropathic 
characteristics has been estimated to be in the range of 7–10%8,24.
Chronic neuropathic pain is more frequent in women (8% versus 5.7% in men) and in 
patients >50 years of age (8.9% versus 5.6% in those <49 years of age), and most commonly 
affects the lower back and lower limbs, neck and upper limbs24. Lumbar and cervical painful 
radiculopathies are probably the most frequent cause of chronic neuropathic pain. Consistent 
with these data, a survey of >12,000 patients with chronic pain with both nociceptive and 
neuropathic pain types, referred to pain specialists in Germany, revealed that 40% of all 
patients experience at least some characteristics of neuropathic pain (such as burning 
sensations, numbness and tingling); patients with chronic back pain and radiculopathy were 
particularly affected25.
Colloca et al. Page 3
Nat Rev Dis Primers. Author manuscript; available in PMC 2017 March 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mechanisms/pathophysiology
Research in the pain field has focused on understanding the plastic changes in the nervous 
system after nerve injury, identifying novel therapeutic targets and in facilitating the transfer 
of knowledge from animal models to clinical practice. We describe briefly the multiple 
causes of neuropathic pain and present an overview of animal and human findings that have 
provided insights on the pathophysiology of neuropathic pain.
Causes and distributions
Central neuropathic pain is due to a lesion or disease of the spinal cord and/or brain. 
Cerebrovascular disease affecting the central somatosensory pathways (poststroke pain) and 
neurodegenerative diseases (notably Parkinson disease) are brain disorders that often cause 
central neuropathic pain26. Spinal cord lesions or diseases that cause neuropathic pain 
include spinal cord injury, syringomyelia and demyelinating diseases, such as multiple 
sclerosis, transverse myelitis and neuromyelitis optica27. By contrast, the pathology of the 
peripheral disorders that cause neuropathic pain predominantly involves the small 
unmyelinated C fibres and the myelinated A fibres, namely, the Aβ and Aδ fibres5. 
Peripheral neuropathic pain will probably become more common because of the ageing 
global population, increased incidence of diabetes mellitus and the increasing rates of cancer 
and the consequence of chemotherapy, which affect all sensory fibres (Aβ, Aδ and C fibres). 
Peripheral neuropathic pain disorders can be subdivided into those that have a generalized 
(usually symmetrical) distribution and those that have a focal distribution (FIG. 2). The most 
clinically important painful generalized peripheral neuropathies include those associated 
with diabetes mellitus (BOX 3), pre-diabetes and other metabolic dysfunctions, infectious 
diseases (mainly HIV infection28 and leprosy29), chemotherapy, immune (for example, 
Guillain-Barre syndrome) and inflammatory disorders, inherited neuropathies and 
channelopathies (such as inherited erythromelalgia, a disorder in which blood vessels are 
episodically blocked then become hyperaemic and inflamed).
The topography of the pain in these disorders typically encompasses the distal extremities, 
often called a ‘glove and stocking’ distribution because the feet, calves, hands and forearms 
are most prominently affected. This distribution pattern is characteristic of dying-back, 
length-dependent, distal peripheral neuropathies involving a distal-proximal progressive 
sensory loss, pain and, less frequently, distal weakness. Less frequently, the pain has a 
proximal distribution in which the trunk, thighs and upper arms are particularly affected; this 
pattern occurs when the pathology involves the sensory ganglia. Painful focal peripheral 
disorders are caused by pathological processes that involve one or more peripheral nerves or 
nerve roots. These disorders include postherpetic neuralgia, post-traumatic neuropathy, 
postsurgical neuropathy, cervical and lumbar polyradiculopathies, pain associated with HIV 
infection, leprosy and diabetes mellitus, complex regional pain syndrome type 2 and 
trigeminal neuralgia30.
Rare inherited channelopathies can show characteristic pain distributions and triggering 
factors. For example, inherited erythromelalgia is due to mutations in SCN9A, which 
encodes the voltage-gated sodium channel Nav1.7 (involved in the generation and 
conduction of action potentials), and is characterized by pain and erythema (reddening) in 
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the extremities, which is exacerbated by heat31. Paroxysmal extreme pain disorder is due to 
a distinct set of mutations in SCN9A that result in a proximal distribution of pain and 
erythema affecting the sacrum and mandible32; pain triggers in those with this condition can 
include mechanical stimuli. In approximately 30% of patients with idiopathic small-fibre 
neuropathy, functional mutations of the Nav1.7 sodium channel that result in hyperexcitable 
dorsal root ganglion neurons have been observed33.
Pain signalling changes
Peripheral neuropathy alters the electrical properties of sensory nerves, which then leads to 
imbalances between central excitatory and inhibitory signalling such that inhibitory 
interneurons and descending control systems are impaired. In turn, transmission of sensory 
signals and disinhibition or facilitation mechanisms are altered at the level of the spinal cord 
dorsal horn neurons. Indeed, preclinical studies have revealed several anatomical, molecular 
and electrophysiological changes from the periphery through to the central nervous system 
(CNS) that produce a gain of function, providing insights into neuropathic pain and its 
treatment (BOX 4). At the periphery, spinal cord and brain, a gain of excitation and 
facilitation and a loss of inhibition are apparent. These changes shift the sensory pathways to 
a state of hyperexcitability, and a sequence of changes over time from the periphery to the 
brain might contribute to the neuropathic pain state becoming chronic.
Ectopic activity in primary afferent fibres might have a key role in the pathophysiology of 
neuropathic pain following peripheral nerve injury. Patients with painful diabetic 
polyneuropathy and traumatic peripheral nerve injury showed a complete loss of ipsilateral 
spontaneous and evoked pain when treated with a peripheral nerve block (with lidocaine, 
which blocks voltage-gated sodium channels)34. Similarly, a blockade of the dorsal root 
ganglion by intraforaminal epidural administration of lidocaine resulted in relief of painful 
and non-painful sensations in patients with phantom limb pain35. Microneurography studies 
have also identified a spontaneous activity — primarily in C fibres — that is related to pain, 
suggesting a potential peripheral mechanism for neuropathic pain36, 37.
Overall, the underlying hyperexcitability in neuropathic pain results from changes in ion 
channel function and expression, changes in second-order nociceptive neuronal function and 
changes in inhibitory interneuronal function.
Ion channel alterations
Neuropathy causes alterations in ion channels (sodium, calcium and potassium) within the 
affected nerves, which can include all types of afferent fibres that then affect spinal and 
brain sensory signalling. For example, increased expression and function of sodium channels 
at the spinal cord terminus of the sensory nerves (mirrored by an enhanced expression of the 
α2δ subunit of calcium channels) lead to increased excitability, signal transduction and 
neurotransmitter release. Indeed, the crucial role of sodium channels is shown by loss or 
gain of pain in humans with inherited channelopathies31. At the same time, a loss of 
potassium channels that normally modulate neural activity is also evident. If an afferent fibre 
is disconnected from the periphery due to an injury or a lesion, there will be sensory loss. 
However, the remnants of the fibres at the injury site can generate ectopic activity (for 
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example, neuroma C fibre afferents), and so pain from a ‘numb’ area results38. The 
remaining intact fibres are hyperexcitable, so-called irritable nociceptors39. As a result, the 
patient can experience ongoing pain, numbness and evoked pains. The altered inputs into the 
spinal cord coupled with increased calcium channel function (through higher expression in 
the nerve terminal) result in increased neurotransmitter release and enhanced excitatory 
synaptic transmission in the nociceptive circuit.
Second-order nociceptive neuron alterations
Enhanced excitability of spinal neurons produces increased responses to many sensory 
modalities, enables low-threshold mechanosensitive Aβ and Aδ afferent fibres to activate 
second-order nociceptive neurons (which convey sensory information to the brain) and 
expands their receptive fields so a given stimulus excites more second-order nociceptive 
neurons, generating the so-called central sensitization40,41. In particular, ongoing discharge 
of peripheral afferent fibres with concomitant release of excitatory amino acids and 
neuropeptides leads to postsynaptic changes in second-order nociceptive neurons, such as an 
excess of signalling due to phosphorylation of N-methyl-D-aspartate (NMDA) and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. These second-
order changes plausibly explain physical allodynia and are reflected by enhanced sensory 
thalamic neuronal activity, as supported by data from animal42 and human studies43. 
Hyperexcitability can also be caused by a loss of γ-aminobutyric acid (GABA)- releasing 
inhibitory interneurons that can also switch to exert consequently excitatory actions at spinal 
levels44. In addition, there are less well-understood functional changes in non-neuronal cells 
within the spinal cord, such as microglia and astrocytes, which contribute to the 
development of hypersensitivity45.
Inhibitory modulation changes
In addition to changes in pain transmission neurons, inhibitory interneurons and descending 
modulatory control systems are dysfunctional in patients with neuropathic pain. Interneuron 
dysfunction contributes to the overall altered balance between descending inhibitions and 
excitations; specifically, neuropathy leads to a shift in excitation that now dominates. 
Consequently, the brain receives altered and abnormal sensory messages. Altered projections 
to the thalamus and cortex and parallel pathways to the limbic regions account for high pain 
ratings and anxiety, depression and sleep problems, which are relayed as painful messages 
that dominate limbic function.
Areas such as the cingulate cortex and amygdala have been implicated in the ongoing pain 
state and comorbidities associated with neuropathic pain46. Projections from these forebrain 
areas modulate descending controls running from the periaqueductal grey (the primary 
control centre for descending pain modulation) to the brainstem and then act on spinal 
signalling. Indeed, numerous studies have shown that the brainstem excitatory pathways are 
more important in the maintenance of the pain state than in its induction.
Noradrenergic inhibitions, mediated through α2-adrenergic receptors in the spinal cord, are 
attenuated in neuropathic pain, and enhanced serotonin signalling through the 5-HT2 and 5-
HT3 serotonin receptors becomes dominant. The noradrenergic system mediates the diffuse 
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noxious inhibitory controls (DNICs), the animal counterpart of the human conditioned pain 
modulation (CPM; FIG. 3), in which one pain inhibits another through descending 
pathways. DNICs (and CPM) are lost or at least partially impaired in those with neuropathy. 
Animals that recruit noradrenergic inhibitions have markedly reduced hypersensitivity after 
neuropathy despite identical levels of nerve damage47, explaining the advantage of using 
medication that manipulates the monoamine system to enhance DNICs in patients by 
blocking descending facilitations.
Pain modulation mechanisms
Some patients with neuropathic pain are moderately affected, whereas others experience 
debilitating pain. Moreover, patients show a large variability in response to distinct 
pharmacological (in terms of type and dose) and non-pharmacological treatments. A key 
factor in this variability might be the way that the pain message is modulated in the CNS. 
The pain signal can be augmented or reduced as it ascends from its entry port (the dorsal 
horn), relayed to the CNS and arrives at the cerebral cortex (the area crucial for 
consciousness). The various pathways and interference can, accordingly, modify the 
assumed correlation between the extent of the peripheral pathology and the extent of the 
pain syndrome. Most patients with neuropathic pain express a pro-nociceptive pain 
modulation profile — that is, pain messages are augmented in the CNS48. Thus, the 
perception of pain can be disinhibited owing to decreased descending endogenous inhibition, 
which is depicted by less-efficient CPM (BOX 1), facilitated through sensitization of 
ascending pain pathways, which is depicted by enhanced temporal summation of painful 
stimulations, or both. Temporal summation is augmented in neuropathic and non-
neuropathic pain, but patients with neuropathic pain present with a higher slope of 
increase48. CPM has been shown to be less efficient in patients with various pain syndromes 
than in healthy controls49.
The prospect of harnessing pain modulation seems promising for a more individualized 
approach to pain management. Indeed, studies have shown that the pain modulation profile 
can predict the development and extent of chronic postoperative pain50–52. If these findings 
are confirmed by larger studies, we can speculate that patients who express a facilitatory 
pro-nociceptive profile could be treated with a drug that reduces the facilitation (such as 
gabapentinoids) and patients who express an inhibitory pro-nociceptive profile could be 
treated with a drug that enhances the inhibitory capacity (for example, serotonin-
noradrenaline reuptake inhibitors)50. Patients who express both less-efficient CPM and 
enhanced temporal summation might need a combination of treatments. Indeed, the level of 
CPM predicts the efficacy of duloxetine (a selective serotonin-noradrenaline reuptake 
inhibitor) in patients; CPM is restored with both duloxetine and tapentadol (a noradrenaline 
reuptake inhibitor). Moreover, the altered pain modulation profile of a patient can be 
reversed towards normality when pain is treated, as exemplified with arthroplasty surgery in 
patients with osteoarthritis; when the diseased joint is replaced, the majority of patients will 
be free of pain and the central and peripheral processes normalize34, 53, 54.
Notably, pain modulation is highly influenced by expectancy-induced analgesia, in which 
changes due to the beliefs and desires of patients and providers55 affect response to 
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treatment for neuropathic pain. In laboratory settings, expectancy-induced analgesia 
influences clinical pain in irritable bowel syndrome56–58, idiopathic and neuropathic pain59. 
For example, Petersen et al.60, 61 tested expectancy-induced analgesia in patients who 
developed neuropathic pain after thoracotomy. Patients received lidocaine in an open (that is, 
patients were told: “The agent you have just been given is known to powerfully reduce pain 
in some patients”) or hidden (“This is a control condition for the active medication”) manner 
in accordance with a previously described protocol62; the results showed a large reduction of 
ongoing pain, maximum wind-up-like pain and an area of hyperalgesia in those in the open 
group, recapitulating previous reports59,60. These findings point to a clinically relevant 
endogenous pain inhibitory mechanism with implications for phenotyping patients with 
neuropathic pain in clinical trial designs and practices. Such effects should be reduced in 
clinical trials and intentionally enhanced in daily clinical practices as a strategy to optimize 
pain management.
Diagnosis, screening and prevention
A system was proposed to determine the level of certainty with which the pain in question is 
neuropathic as opposed, for example, to nociceptive pain5 (FIG. 4a). If the patient’s history 
suggests the presence of a neurological lesion or disease and the pain could be related to 
such (for example, using validated screening tools) and the pain distribution is 
neuroanatomically plausible, the pain is termed ‘possible’ neuropathic pain. ‘Probable’ 
neuropathic pain requires supporting evidence obtained by a clinical examination of sensory 
signs (for example, bedside testing and quantitative sensory testing). ‘Definite’ neuropathic 
pain requires that an objective diagnostic test confirms the lesion or disease of the 
somatosensory nervous system (for example, neurophysiological tests and skin biopsy). A 
minimum finding of probable neuropathic pain should lead to treatment.
On the basis of the assumption that characteristic qualities indicative of neuropathic pain in 
sensory perception are present, several screening tools have been developed to identify 
neuropathic pain conditions or neuropathic components to chronic pain syndromes63 (BOX 
2). These simple to use patient-reported questionnaires, for example, the DN4 or 
painDETECT22,64, assess characteristic neuropathic pain symptoms (such as burning, 
tingling, sensitivity to touch, pain caused by light pressure, electric shock-like pain, pain to 
cold or heat, and numbness) and can distinguish between neuropathic and non-neuropathic 
pain with high specificity and sensitivity when applied in patients with chronic pain. Other 
tools, such as the Neuropathic Pain Symptom Inventory (NPSI)65, have been more 
specifically developed for the quantification of neuropathic symptoms and dimensions and 
have contributed to further phenotype individual patients particularly for clinical trials.
Confirmatory tests for nerve damage
Different psychophysical and objective diagnostic tests are available to investigate 
somatosensory pathway function, including bedside evaluation and assessment of sensory 
signs as well as neurophysiological techniques, skin biopsy and corneal confocal 
microscopy (FIG. 4b). Of these, sensory evaluation, neurophysiological techniques and 
quantitative sensory testing are routinely used.
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Bedside sensory assessment of sensory signs
Neuropathic pain presents as a combination of different symptoms and signs66. Touch, 
pinprick, pressure, cold, heat, vibration, temporal summation and after sensations can be 
examined at the bed side, whereby the patient describes the sensation after a precise and 
reproducible stimulus is applied67. To assess either a loss (negative sensory signs) or a gain 
(positive sensory signs) of somatosensory function, the responses are graded as normal, 
decreased or increased. The stimulus-evoked (positive) pain types are classified as 
hyperalgesic (experiencing increased pain from a stimulus that is normally perceived as less 
painful) or allodynic (experiencing pain from a stimulus that does not normally trigger a 
pain response), and according to the dynamic or static character of the stimulus.
Quantitative sensory testing
Quantitative sensory tests use standardized mechanical and thermal stimuli to test the 
afferent nociceptive and non-nociceptive systems in the periphery and the CNS. Quantitative 
sensory tests assess loss and gain of function of the entire different afferent fibre classes 
(Aβ, Aδ and C fibres), which is a distinct advantage over other methods68. The German 
Research Network on Neuropathic Pain69 proposed a battery of quantitative sensory tests 
that consists of 13 parameters to help identify somatosensory phenotypes of patients with 
neuropathic pain. These thermal and mechanical tests include the determination of detection 
thresholds for cold, warm, paradoxical heat sensations and touch and vibration; 
determination of pain thresholds for cold and heat stimulations, pinprick and blunt pressure; 
and determination of allodynia and pain summation. Recently, normative data from a large 
database of healthy individuals have helped to determine gain or loss of sensory function in 
age-matched and sex-matched patients with neuropathic pain70,71. Accordingly, pathological 
values of positive and negative signs have been determined for most variables (FIG. 5).
Neurophysiological techniques
Laser-evoked potentials (LEPs) are widely considered the most reliable neurophysiological 
tool to assess nociceptive functions67,72. For example, nerve conduction studies, trigeminal 
reflexes and somatosensory-evoked potentials — the Aβ fibre-mediated standard 
neurophysiological techniques — do not provide information on nociceptive pathways. 
However, they are still useful to identify damage along the somatosensory pathways and are 
widely used for assessing peripheral and CNS diseases that cause neuropathic pain73. Laser 
stimulations selectively activate Aδ and C nociceptors in the superficial layers of the skin74.
LEPs related to Aδ fibre activation have been standardized for clinical application. The 
responses to stimulation are recorded from the scalp and consist of waveforms with different 
latencies. In diseases associated with damage to the nociceptive pathway, LEPs can be 
absent, reduced in amplitude or delayed in latency75–77. Among nociceptive-evoked 
potentials, contact heat- evoked potentials are also widely used in assessing neuropathic 
pain78. Concentric electrodes have also been introduced to measure pain-related evoked 
potentials and the small-fibre involvement in neuropathic pain79. Nevertheless, some studies 
suggest that concentric electrodes also activate non-nociceptive Aβ fibres; hence, pain-
related evoked potential recording is not suitable for assessing nociceptive systems78.
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Skin biopsy
Skin biopsy to assess epidermal innervation is regarded as the most sensitive tool for 
diagnosing small-fibre neuropathies80. The technique is useful because the skin has 
widespread unmyelinated C fibre terminals, with relatively few small myelinated Aδ fibres 
that lose their myelin sheath and reach the epidermis as unmyelinated free nerve 
endings81,82. However, the relationship between skin biopsy data and neuropathic pain is 
still unclear. One study in 139 patients with peripheral neuropathy suggested that a partial 
sparing of intraepidermal nerve fibres, as assessed with skin biopsy, is associated with 
provoked pain83.
Corneal confocal microscopy
As a non-invasive in vivo technique, corneal confocal microscopy can be used to quantify 
corneal nerve fibre damage (to small myelinated Aδ and unmyelinated C fibres) in patients 
with peripheral neuropathies84, 85. However, this technique has several limitations, such as 
the high cost and the reduced availability in most clinical centres. Furthermore, whether 
some conditions (such as dry eye syndrome and Sjögren syndrome, eye diseases or previous 
eye surgery) influence the corneal confocal variables is still unclear86. No study has reliably 
investigated the association between corneal confocal microscopy variables and neuropathic 
pain.
Prevention
Given that the available treatments for neuropathic pain have meaningful but modest benefits 
(see Management), interventions that prevent neuropathic pain can have a substantial effect 
on public health. Indeed, increased attention to prevention has the potential to reduce the 
disability experienced by many patients with chronic neuropathic pain. Leading a healthy 
lifestyle and education regarding pain-causing health conditions are important components 
of prevention, especially in those who are at greater risk of developing neuropathic pain87. 
Prevention programmes that combine mutually reinforcing medical and behavioural 
interventions might lead to greater preventive benefits.
The identification of risk factors is essential to prevent neuropathic pain developing in at-risk 
individuals. Primary prevention strategies (in generally healthy but at-risk individuals) 
include the live attenuated88,89 and subunit adjuvanted90,91 herpes zoster vaccines, which 
both reduce the likelihood of developing herpes zoster infections in individuals ≥50 years of 
age88–91, and therefore, reduce the likelihood of postherpetic neuralgia. Secondary 
prevention involves administering preventive interventions to individuals who are 
experiencing an illness, injury or treatment that can cause chronic neuropathic pain. 
Examples of this approach include the perioperative treatment of surgical patients to prevent 
chronic postsurgical pain92 and the use of antiviral or analgesic treatment in patients with 
herpes zoster infection93. Furthermore, proper management of health conditions, such as 
diabetes mellitus, may prevent neuropathic pain before it even presents94.
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Management
The management of neuropathic pain generally focuses on treating symptoms because the 
cause of the pain can be rarely treated; furthermore, the management of aetiological 
conditions, such as diabetes mellitus, is typically insufficient to relieve neuropathic pain. 
Patients with neuropathic pain generally do not respond to analgesics such as 
acetaminophen, NSAIDs or weak opioids such as codeine. The traditional approach to the 
management of a patient with neuropathic pain is to initiate treatment with conservative 
pharmacological and complementary therapies before interventional strategies, such as nerve 
blocks and neuromodulation, are used. However, the limited efficacy of the drugs, the ageing 
population of patients, polypharmacy in elderly patients and opioid-related adverse effects 
have resulted in an increasing use of interventional therapies. Clinical studies are lacking to 
help guide the physician in the optimal sequence of therapy in a given patient.
Medical intervention
Numerous therapeutic recommendations, with different classes of drug, for neuropathic pain 
have been proposed95–99. On the basis of a systematic review and meta-analysis of all drug 
studies reported on since 1966, including unpublished trials100, pregabalin (a GABA 
analogue), gabapentin (a GABA inhibitor), duloxetine (a serotonin-noradrenaline reuptake 
inhibitor) and various tricyclic antidepressants have strong recommendations for use and are 
recommended as first-line treatments for peripheral and central neuropathic pain. High-
concentration capsaicin (the active component of chili peppers) patches, lidocaine patches 
and tramadol (an opioid with serotonin and noradrenaline reuptake inhibition effects) have 
weak evidence in support of their use and are recommended as second-line treatments for 
peripheral neuropathic pain only. Strong opioids and botulinum toxin A (administered by 
specialists) have weak recommendations for use as third-line treatments. However, most of 
these treatments have moderate efficacy based on the number needed to treat (NNT; that is, 
the number of patients necessary to treat to obtain one responder more than the comparison 
treatment, typically placebo) for obtaining 50% of pain relief101 (TABLE 1). Furthermore, 
pharmacological treatments for chronic neuropathic pain are effective in <50% of patients 
and may be associated with adverse effects that limit their clinical utility101.
First-line treatments
Antidepressants and antiepileptics have been the most studied drugs in neuropathic pain. 
Among antidepressants, tricyclic antidepressants, such as amitriptyline, and serotonin-
noradrenaline reuptake inhibitors, such as duloxetine, have confirmed efficacy in various 
neuropathic pain conditions. Their analgesic efficacy seems largely mediated by their action 
on descending modulatory inhibitory controls, but other mechanisms have been proposed 
(including an action on β2 adrenoceptors)102. Among antiepileptics, the efficacy of 
pregabalin and gabapentin, including extended-release formulations, is best established for 
the treatment of peripheral neuropathic pain and, to a lesser extent, spinal cord injury pain. 
However, the number of negative trials has increased over the past 5 years. The analgesic 
effects of these drugs are mainly related to a decrease in central sensitization through 
binding to the α2δ subunit of calcium voltage-gated channels103.
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Combination of pregabalin or gabapentin with a tricyclic antidepressant or opioid at lower 
doses has resulted in beneficial effects as compared to monotherapy in peripheral 
neuropathic pain100,101,104. However, the efficacy and adverse effects of high-dose 
monotherapy were similar to those of moderate-dose combination therapy in patients with 
diabetic neuropathic pain who did not respond to monotherapy at moderate doses105. These 
studies provide a rationale for the use of combinations of drugs, at moderate dosages, in 
patients who are unable to tolerate high-dose monotherapy.
Second-line treatments
Lidocaine is thought to act on ectopic neuronal discharges through its sodium channel-
blocking properties. The efficacy of lidocaine 5% patches has been assessed in focal 
peripheral postherpetic neuralgia, but their therapeutic gain is modest compared with 
placebo106,107. Capsaicin initially activates transient receptor potential cation channel 
subfamily V member 1 (TRPV1) ligand-gated channels on nociceptive fibres, leading to 
TRPV1 desensitization and defunctionalization. The sustained efficacy of a single 
application of a high-concentration capsaicin patch (8%) has been reported in postherpetic 
neuralgia108, as well as diabetic104 and non-diabetic painful neuropathies109. The long-term 
safety of repeated applications seems favourable based on open studies, but there are no 
longterm data on the effects on epidermal nerve fibres in patients with neuropathic pain101. 
Tramadol, an opioid agonist and serotonin-noradrenaline reuptake inhibitor, has also been 
shown to be effective, mainly in peripheral neuropathic pain; its efficacy is less established 
in central neuropathic pain101.
Third-line treatments
Botulinum toxin A is a potent neurotoxin commonly used for the treatment of focal muscle 
hyperactivity and has shown efficacy of repeated administrations over 6 months, with 
enhanced effects of the second injection110. The toxin has a beneficial role in the treatment 
of peripheral neuropathic pain (for example, diabetic neuropathic pain, postherpetic 
neuralgia and trigeminal neuralgia)110–112.
Opioid agonists, such as oxycodone and morphine, are mildly effective101, but there is 
concern about prescription opioid-associated overdose, death, diversion, misuse and 
morbidity113.
There are weak, negative or inconclusive recommendations for the use of all other drug 
treatments for neuropathic pain in general. Antiepileptics other than α2δ ligands (for 
example, topiramate, oxcarbazepine, carbamazepine, valproate, zonisamide, lacosamide and 
levetiracetam) fall into these categories, although some agents are probably effective in 
subgroups of patients. Oromucosal cannabinoids have been found to be variably effective in 
pain associated with multiple sclerosis and in peripheral neuropathic pain with allodynia, but 
several unpublished trials were negative on the primary outcome. Results for selective 
serotonin reuptake inhibitors, NMDA antagonists, mexiletine (a non-selective voltage-gated 
sodium channel blocker) and topical clonidine (an α2-adrenergic agonist and imidazoline 
receptor agonist) have generally been inconsistent or negative except in certain subgroups.
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Emerging treatments
A few drugs targeting novel mechanisms of action are under clinical development for the 
treatment of peripheral neuropathic pain. These include, in particular, subtype selective 
sodium channel-blocking agents, particularly Nav1.7 antagonists114, and EMA401, a novel 
angiotensin type II antagonist that has been found to be effective in a phase II clinical trial in 
postherpetic neuralgia115. Although still in the preclinical phase, studies show promising 
results of stem cell treatment for neuropathic pain116,117.
Interventional therapies
Interventional treatments, such as nerve blocks or surgical procedures that deliver drugs to 
targeted areas, or modulation of specific neural structures, provide alternative treatment 
strategies in selected patients with refractory neuropathic pain118,119 (FIG. 6). Although 
generally safe (see below), spinal cord stimulation and peripheral nerve stimulation have 
been associated with hardware-related, biological complications, such as infections and 
programming-related or treatment-related adverse effects (including painful 
paraesthesias)120,121.
Neural blockade and steroid injections
A perineural injection of steroids provides transient relief (1–3 months) for trauma-related 
and compression-related peripheral neuropathic pain122. Systematic reviews and meta-
analysis of epidural steroid injections for the treatment of cervical and lumbar 
radiculopathies indicate an immediate modest reduction in pain and function of <3 months 
duration, but had no effects on reducing the risk for subsequent surgery119,123,124. Epidural 
local anaesthetic and steroid nerve blocks were given a weak recommendation for the 
treatment of lumbar radiculopathy and acute zoster-associated neuropathic pain119. 
Although sympathetic ganglion blocks have been used to treat pain in some patients with 
complex regional pain syndromes (also known as causalgia and reflex sympathetic 
dystrophy), the evidence for long-term benefit is weak119.
Spinal cord stimulation
Low-intensity electrical stimulation of large myelinated Aβ fibres was introduced based on 
the gate control theory125 as a strategy to modulate the pain signals transmitted by the 
unmyelinated C fibres. The most commonly used and the best-studied neuromodulation 
strategy has been spinal cord stimulation, in which a monophasic square-wave pulse 
(frequency ranging 30–100 Hz) is applied, resulting in paraesthesia in the painful region126. 
Newer stimulation parameters, such as burst (40 Hz burst with five spikes at 500 Hz per 
burst) and high-frequency (10 kHz with sinusoidal waveforms) spinal cord stimulation, 
provide paraesthesia-free stimulation and equivalent or better pain relief compared with the 
monophasic square-wave pulse127,128.
The relative safety and reversibility of spinal cord stimulation, as well as its cost-
effectiveness over the long term have made it an attractive strategy for managing patients 
with refractory chronic neuropathic pain129–131. Systematic reviews, randomized controlled 
trials and several case series provide evidence for the long-term efficacy of spinal cord 
stimulation when combined with medical treatment compared with medical management in 
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various pain neuropathies132–134, and has been shown to offer sustained results at 24 months 
of treatment135,136. Two randomized trials in individuals with painful diabetic neuropathy 
reported greater reduction in pain and improvements in measures of quality of life compared 
with controls137,138. Current European guidelines provide a weak recommendation for 
spinal cord stimulation (combined with medical treatment) in, for example, diabetic 
neuropathic pain118,119,139. The success of spinal cord stimulation for neuropathic pain may 
depend on the appropriate selection of patients based on psychological traits, sensory 
phenotype, enhanced central sensitization and reduced CPM140,141.
Dorsal root ganglion, peripheral nerve and peripheral nerve field stimulation
Neurostimulation of afferent fibres outside the spinal cord (for example, the dorsal root 
ganglion, which contains the cell bodies of sensory neurons, and peripheral nerves) and 
subcutaneous peripheral nerve field stimulation have been reported to provide pain relief in 
various chronic neuropathic pain states, including occipital neuralgia and postherpetic 
neuralgia142,143. A multicentre prospective cohort study in patients with chronic neuropathic 
pain reported that dorsal root ganglion stimulation provided 56% pain reduction with a 60% 
responder rate (>50% reduction in pain)144. These preliminary observations are being 
examined with controlled trials.
Epidural and transcranial cortical neurostimulation
Epidural motor cortex stimulation (ECMS), repetitive transcranial magnetic stimulation 
(rTMS) and transcranial direct current stimulation (tDCS) of the pre-central motor cortex at 
levels below the motor threshold have been proposed as treatment options for patients with 
refractory chronic neuropathic pain145,147. Cortical neurostimulation may reduce pain-
related thalamic hyperactivity or activate descending inhibitory pathways. Meta-analysis 
reports suggest that 60–65% of patients respond (>40% pain reduction) to EMCS147. ECMS 
is a neurosurgical procedure that requires precise intra-operative placement of the 
stimulating electrode over the motor cortex region corresponding to the painful body part for 
optimal outcome.
rTMS and tDCS are non-invasive therapies that involve neurostimulation of brain areas of 
interest via magnetic coils or electrodes on the scalp. Repetitive sessions (5–10 sessions over 
1–2 weeks) with high-frequency rTMS (5–20 Hz) have shown benefits in a mixture of 
central, peripheral and facial neuropathic pain states, with effects lasting >2 weeks after the 
stimulation. tDCS has been reported to be beneficial in reducing several peripheral 
neuropathic conditions148. Current European guidelines include a weak recommendation for 
the use of EMCS and rTMS in refractory chronic neuropathic pain and tDCS for peripheral 
neuropathic pain133. Contraindications of rTMS include a history of epilepsy and the 
presence of aneurysm clips, deep brain electrodes, cardiac pacemakers and cochlear 
implants.
Deep brain stimulation
The use of long-term intracranial stimulation for neuropathic pain remains controversial. 
Multiple sites for deep brain stimulation, including the internal capsule, various nuclei in the 
sensory thalamus, periaqueductal and periventricular grey, motor cortex, septum, nucleus 
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accumbens, posterior hypothalamus and anterior cingulate cortex, have been examined as 
potential brain targets for pain control149. The UK National Institute for Health and Care 
Excellence (NICE) guidelines recognize that the procedure can be efficacious in some 
patients who are refractory to other forms of pain control, but current evidence on the safety 
of deep brain stimulation shows significant potential risks, such as intra-operative seizure, 
lead fractures and wound infections98. Contrary to the NICE guidelines, the current 
European guidelines give inconclusive recommendations139.
Intrathecal therapies
Intrathecal therapies have been developed to deliver drugs to targeted nerves through an 
implanted and refillable pump in patients with severe and chronic pain that is refractory to 
conservative treatments, including psychological, physical, pharmacological and 
neuromodulation therapies150,151. The report from the 2012 Polyanalgesic Consensus 
Conference highlighted that this therapy is associated with risks of serious morbidity and 
mortality and made recommendations to reduce the incidence of these serious adverse 
effects152. The only US FDA-approved drugs for use with such devices are morphine and 
ziconotide (an N-type calcium channel antagonist)153. The most frequently reported adverse 
reactions associated with intrathecal ziconotide are dizziness, nausea, confusion, memory 
impairment, nystagmus (uncontrolled movement of the eyes) and an increase in the levels of 
serum creatine kinase. Ziconotide is contraindicated in patients with a history of psychosis, 
and patients should be monitored for evidence of cognitive impairment, hallucinations or 
changes in mood and consciousness. No high-quality randomized trials have been conducted 
to assess the efficacy of ziconotide and morphine; hence, the recommendations are a 
consensus of experts based on clinical experience or case series.
Physical therapies
Physical therapy, exercise and movement representation techniques (that is, treatments such 
as mirror therapy and motor imagery that use the observation and/or imagination of normal 
pain-free movements) have been suggested to be beneficial in neuropathic pain 
management154,155. For example, mirror therapy and motor imagery are effective in the 
treatment of pain and disability associated with complex regional pain syndrome type I and 
type II156. The quality of evidence supporting these interventions for neuropathic pain is 
weak and needs further investigation154,157.
Psychological therapies
People with chronic pain are not passive; they actively attempt to change the causes of pain 
and change their own behaviour in response to pain. However, for many patients, such 
change without therapeutic help is unachievable, and repeated misdirected attempts to solve 
the problem of pain drive them further into a cycle of pain, depression and disability158. At 
present, there is no evidence for identifying who is at risk of untreatable, difficult to manage 
neuropathic pain and who might benefit from psychological intervention, although research 
is underway on the former159.
Psychological interventions are designed to promote the management of pain and to reduce 
its adverse consequences. Treatments are often provided after pharmacological or physical 
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interventions have failed, although they could be introduced earlier and in concert with non-
psychological interventions. Cognitive-behavioural therapy (CBT) has received the most 
research attention; however, CBT is not a single treatment and can be usefully thought of as 
a family of techniques that are woven together by a clinical narrative of ‘individual change’ 
delivered by therapists who actively manage treatment. Such treatments address mood 
(typically anxiety and depression), function (including disability) and social engagement, as 
well as indirectly targeting analgesia. Secondary outcomes are sometimes reported because 
they are deemed important to treatment delivery (for example, therapeutic alliance and self-
efficacy) or because they are valued by one or more stakeholder (for example, return to work 
and analgesic use).
A Cochrane systematic review of psychological interventions for chronic pain analysed data 
from 35 trials, which showed small-to-moderate effects of CBT over comparisons such as 
education, relaxation and treatment as usual160. In a companion review of 15 trials 
delivering treatment via the Internet, a similar broadly positive conclusion emerged, 
although the confidence in the estimates of effects was low161. Psychological treatments 
other than behavioural therapy and CBT were considered in this review, but none was of 
sufficient quality to include. Another Cochrane review of trials specifically undertaken in 
patients with neuropathic pain found no evidence for or against the efficacy and safety of 
psychological interventions for chronic neuropathic pain162, which is not surprising given 
the similar findings for non-psychological interventions163. An urgent need for studies of 
treatments that are designed specifically for patients with neuropathic pain exists, in 
particular, those with painful diabetic neuropathy, which is a growing problem164. 
Specifically, studies of CBT are needed with content that is specifically designed to meet the 
psychosocial needs of patients with neuropathy, in particular, with regard to the multiple 
sensory challenge, comorbidity and polypharmacy165. A recognition that neuropathic pain 
increases with age will also mean that an understanding of later-life accommodation to 
illness will be important166. In addition, a methodological focus on individual experience 
and trajectories of change is needed, either through single case experiments or through 
ecological momentary assessment167. Furthermore, communication technology, in 
particular, the use of mobile health innovation, is likely to play an important part in future 
solutions. However, how to manage effective therapeutic relationships at a distance, and how 
technology can augment and improve face-to-face CBT remain to be clarified168. Technical 
psychological variables — such as catastrophic thinking, acceptance or readiness to change 
— should be relegated to process variables. Conversely, a pragmatic focus on patient-
reported outcomes will be essential to reduce pain, improve mood and reduce disability, 
which will ultimately improve quality of life.
Quality of life
Neuropathic pain can substantially impair quality of life as it often associates with other 
problems, such as loss of function, anxiety, depression, disturbed sleep and impaired 
cognition. Measures of health-related quality of life (HRQOL) that capture broad 
dimensions of health including physical, mental, emotional and social functioning are 
increasingly used when assessing the efficacy of different interventions to manage chronic 
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neuropathic and non-neuropathic pain. It is mainly useful when calculating quality-adjusted 
life years, which are necessary for cost-utility analyses.
The most commonly used HRQOL instruments are general, whereas others have been 
designed specifically for those with neuropathic pain. Meyer-Rosberg and colleagues 
validated both the 36-Item Short Form Health Survey (SF-36) and the Nottingham Health 
Profile (NHP) in the assessment of HRQOL in neuropathic pain related to peripheral nerve 
or nerve root lesions in patients attending multidisciplinary pain clinics169. The scores of all 
eight dimensions (vitality, physical functioning, bodily pain, general health perceptions, 
physical role functioning, emotional role functioning, social role functioning and mental 
health) in the SF-36 were significantly lower in those with neuropathic pain than in the 
general population, which is in line with another study170.
The onset of neuropathy in patients with diabetes mellitus has been shown to significantly 
decrease all aspects of quality of life171. If diabetic polyneuropathy is accompanied by pain, 
both physical and mental components of quality of life are further affected172. A recent 
study also showed that both EuroQol five dimensions (EQ-5D) and Short Form-6 dimension 
(SF-6D) questionnaires can discriminate between chronic pain with or without neuropathic 
pain173. Furthermore, the role of psychological factors in impairing quality of life in 
neuropathic pain has been analysed174, showing, for example, that pain catastrophizing was 
associated with decreased HRQOL174. The SF-36 and the EQ-5D have been the most 
commonly used instruments in clinical trials to assess the efficacy of treatments, such as 
gabapentin in postherpetic neuralgia175, diabetic polyneuropathy176 and neuropathic pain 
due to peripheral nerve injury170; the efficacy of duloxetine in diabetic peripheral 
neuropathy177; and the efficacy of spinal cord stimulation in diabetic polyneuropathy178.
Outlook
Although nervous system mechanisms underlying chronic neuropathic pain have been 
uncovered through animal and human research, the development of novel interventions with 
improved efficacy and tolerability has been slow. New therapeutic approaches as well as 
improved clinical trial designs, specifically addressing genotypic and phenotypic profiles, 
have great promise to build on recent advances in basic and translational research.
Clinical trial design
The explanations for the slow progress in identifying treatments with improved efficacy that 
are receiving the greatest attention are inadequate clinical trial assay sensitivity and the need 
to target treatment to patients who are most likely to respond179,180. Assay sensitivity refers 
to the ability of a clinical trial to distinguish an efficacious treatment from placebo (or 
another comparator). The possibility that recent neuropathic pain clinical trials suffer from 
limited assay sensitivity is consistent with the observation that a considerable number of 
recent trials in patients with neuropathic pain investigating medications with well-
established efficacy have returned negative results7,181. For example, a recent analysis of 
neuropathic pain trials showed that assay sensitivity was compromised by including patients 
with highly variable baseline pain ratings182, which suggests that trials might have greater 
assay sensitivity if highly variable baseline pain ratings were an exclusion criterion115.
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The outcomes of clinical trials in neuropathic pain have generally shown modest efficacy, 
with the NNTs for 50% pain relief ranging from six to eight for positive studies in the latest 
meta-analysis101. Several reasons could account for these results179,181, including high 
placebo responses, variability in the diagnostic criteria used for neuropathic pain in clinical 
trials and limited assay sensitivity. Thus, it has been proposed that an alternative therapeutic 
approach to neuropathic pain should incorporate stratification of patients according to 
clinical phenotypes (signs and symptoms)66,77,183,184, whereas most trials have simply 
classified patients according to aetiology.
Phenotyping
Several clinical trials provide support for the relevance of phenotypic subgrouping of 
patients, which has the potential to lead to a more personalized pain therapy in the 
future107,110,185,186. In particular, two phenotypes — the presence of mechanical allodynia 
and preserved nociceptive function — are often combined and seem to predict the response 
to systemic and topical sodium channel blockers, botulinum toxin A and clonidine gel in 
recent clinical trials107,110,185. Indeed, any personalized pain treatments will rely on the 
ability to select patients who are likely to respond187.
The strongest evidence showing that profiles of signs and symptoms can identify treatment 
responders stems from a trial in which patients who were defined as having an irritable 
nociceptor phenotype experienced a greater decrease in pain with oxcarbazepine versus 
placebo than those without this phenotype186. This is the only trial in which a pre-specified 
primary analysis demonstrated a difference in treatment versus placebo response in patient 
subgroups identified by phenotyping. These results are very promising, but require 
replication as well as use of phenotyping measures that would be suitable for larger 
confirmatory trials and use in clinical practice188. Phenotyping could also be used to test 
whether certain patients have a more robust response to non-pharmacological treatments, for 
example, invasive, psychological and complementary interventions188, as well as to identify 
which patients are most likely to respond to combinations of treatments. Indeed, given the 
importance of expectations and psychological and social factors — including adaptive 
coping and catastrophizing — in the development and maintenance of chronic neuropathic 
pain, it would not be surprising if phenotyping has a great part to play in demonstrating the 
efficacy of psychological interventions as it does for medications.
To advance the design, execution, analysis and interpretation of clinical trials of pain 
treatments, several public-private partnerships have undertaken systematic efforts to increase 
assay sensitivity and provide validated approaches for phenotyping patients and identifying 
those who are most likely to respond to treatment. These efforts — which include 
ACTTION (www.acttion.org), EuroPain (www.imieuropain.org) and the German Research 
Network on Neuropathic Pain (www.neuro.med.tu-muenchen.de/dfns/) — are providing an 
evidence base for the design of future neuropathic pain clinical trials and for the 
development of mechanism-based approaches to personalized neuropathic pain treatment.
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Personalized pain medicine
Personalized medical care refers to the principle that patients can be stratified such that each 
patient receives the most effective and tolerable treatment for their individual needs. Patients 
can be stratified on several levels: clinical phenotype, detailed sensory profiling, genetics 
and potentially (in the future) using cellular models to facilitate treatment choice. Close 
consultation with the patient is required and this involves complex discussions around the 
uncertainties of genetic risk and the balance between efficacy and tolerability of potential 
treatments. Human genetics studies have demonstrated that Nav1.7 is a crucial pain 
target189, and therapeutics aimed at targeting Nav1.7 provide an example of a situation in 
which testing for specific genetic mutations can inform patient care. Loss-of-function 
mutations lead to congenital insensitivity to pain and gain-of-function mutations cause rare 
inherited pain disorders, including inherited erythromelalgia31, paroxysmal extreme pain 
disorder32 and idiopathic small-fibre neuropathy (which involves pain and small-fibre 
degeneration in the extremities)33.
Genetic information can, therefore, inform diagnostics; however, the interpretation of 
genetic results is complex and should be accompanied by functional analysis of mutant ion 
channels wherever possible190. For instance, in the context of small-fibre neuropathy, 
mutations might not be fully penetrant. Finding a mutation in SCN9A may have immediate 
implications for treatment in choosing a drug with activity against voltage-gated sodium 
channels (not normally first-line agents in the treatment of neuropathic pain), such as 
mexiletine, which is not recommended in the treatment of neuropathic pain but is used in 
inherited erythromelalgia, in which mexiletine has proven efficacy in normalizing abnormal 
channel properties in vitro191 and clinical efficacy in individual cases. A further step has 
been taken in using structural modelling of Nav1.7 to predict what treatment a specific 
mutation will respond to192; the modelling results were used to predict the efficacy of 
carbamazepine (a voltage-gated sodium channel blocker) in inherited erythromelalgia 
associated with the SCN9A S241T mutation193. Furthermore, the generation of nociceptors 
in vitro using patient-derived induced pluripotent stem cells is now possible. In rare 
Mendelian pain disorders (such as inherited erythromelalgia), these nociceptors have been 
shown to be hyperexcitable194. Treatments targeting Nav1.7 can be screened in such cellular 
models and related to clinical efficacy as proof of concept before their use in patients (these 
nociceptors have been shown to be hyperexcitable in inherited erythromelalgia194).
Genetic stratification is more challenging in common acquired neuropathic pain states, such 
as painful diabetic neuropathy, because such conditions are polygenic and subject to 
considerable environmental interaction. Thus, the relevance of an individual target such as 
Nav1.7 in these conditions is less clear. Despite these limitations, the prospect of 
personalized medicine is a step forward towards promising pain management strategies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Box 1
Key terms
Action potential
An electrical event in which the membrane potential of a cell in the nervous system 
rapidly rises and falls to transmit electrical signals from cell to cell.
Allodynia
Pain caused by a normally non-painful stimulus.
Aβ fibres
Sensory nerve fibres with a thick myelin sheath, which insulates the axon of the cell and 
normally promotes the conduction of touch, pressure, proprioception and vibration 
signals (35–90 metres per second).
Aδ fibres
Sensory nerve fibres with a myelin sheath, which insulates the axon of the cell and 
promotes the conduction of cold, pressure and pain signals (5–30 metres per second), that 
produce the acute and sharp experience of pain.
C fibres
Unmyelinated pain nerve fibres that respond to warmth and a range of painful stimuli by 
producing a long-lasting burning sensation due to a slow conduction speed (0.5–2 metres 
per second).
Chemoreceptors
Receptors that transduce chemical signals.
Complex regional pain syndromes
Also known as causalgia and reflex sympathetic dystrophy, complex regional pain 
syndromes are conditions that are characterized by the presence of chronic, intense pain 
(often in one arm, leg, hand or foot) that worsens over time and spreads in the affected 
area. These conditions are typically accompanied by a colour or temperature change of 
the skin where the pain is felt.
Conditioned pain modulation
A reduction of a painful test stimulus under the influence of a conditioning stimulus.
Dynamic mechanical allodynia
A type of mechanical allodynia that occurs when pain is elicited by lightly stroking the 
skin.
Expectancy-induced analgesia
A reduction of pain experience due to anticipation, desire and belief of hypoalgesia or 
analgesia.
Colloca et al. Page 31
Nat Rev Dis Primers. Author manuscript; available in PMC 2017 March 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hyperalgesia
A heightened experience of pain caused by a noxious stimulus.
Hypoalgesia
A decreased perception of pain caused by a noxious stimulus.
Mechanoreceptors
A sensory receptor that transduces mechanical stimulations.
Nociceptors
A peripheral nervous system receptor that is responsible for transducing and encoding 
painful stimuli.
Paradoxical heat sensation
An experienced sensation of heat provoked by a cold stimulus.
Provoked pain
Pain provoked by applying a stimulus.
Pruriceptors
Sensory receptors that transduce itchy sensations.
Second-order nociceptive neurons
Nociceptive neurons in the central nervous system that are activated by the Aβ, Aδ and C 
afferent fibres and convey sensory information from the spinal cord to other spinal 
circuits and the brain.
Static pain
Another kind of mechanical hyperalgesia in those with neuropathic pain when pain is 
provoked after gentle pressure is applied on the symptomatic area.
Temporal summation
The phenomenon in which progressive increases in pain intensity are experienced during 
the repetition of identical nociceptive stimuli.
Thermoreceptors
Sensory receptors that respond to changes in temperature.
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Box 2
Validated screening tools for neuropathic pain
Symptom and clinical examination items can be assessed using distinct validated 
screening tools. The most common tools are listed below.
Leeds Assessment of Neuropathic Symptoms and Signs*
• Four symptom items (pricking, tingling, pins and needles; electric shocks; hot 
or burning sensations; and pain evoked by light touching)
• One item related to skin appearance (mottled or red)
• Two clinical examination items (touch-evoked allodynia and altered pinprick 
sensation)
Douleur Neuropathique 4 questions‡
• Seven symptom items (burning, painful cold, electric shocks, tingling, pins 
and needles, numbness and itching)
• Three clinical examination items (touch hypoaesthesia (reduced sense), 
pinprick hypoaesthesia and brush-evoked allodynia)
Neuropathic Pain Questionnaire§
• Seven sensory descriptors (burning pain, shooting pain, numbness, electrical-
like sensations, tingling pain, squeezing pain and freezing pain)
• Three items related to provoking factors (overly sensitive to touch, touch-
evoked pain and increased pain due to weather change)
• Two items describing affect (unpleasantness and overwhelming)
painDETECT||
• Seven weighted symptom items (burning, tingling or prickling, touch-evoked 
pain, electric shocks, temperature-evoked pain, numbness and pressure-
evoked pain)
• Two items related to spatial (radiating pain) and temporal characteristics
ID Pain¶
• Five symptom items (pins and needles, hot or burning, numbness, electrical 
shocks and touch-evoked pain)
• One item related to location (joints)
Neuropathic Pain Symptom Inventory#
• Ten descriptors (burning, pressure, squeezing, electrical shocks, stubbing, 
pain evoked by brushing, pain evoked by pressure, pain evoked by cold 
stimuli, pins and needles, and tingling)
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• Two temporal items (the temporal sequence of spontaneous ongoing pain and 
paroxysmal pain)
• Five clinically relevant dimensions (evoked pain, paroxysmal pain, abnormal 
sensations, superficial and deep components of spontaneous ongoing pain)
*See REF 23. ‡See REF. 22. §See REF 195. ||See REF 64. ¶See REF 196. #See REF 65.
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Box 3
Neuropathic pain and diabetes mellitus
Painful chronic neuropathy in patients with diabetes mellitus ranges from 10% to 26%38. 
Although risk factors and potential mechanisms underlying neuropathy have been studied 
extensively, the aetiology of the painful diabetic neuropathy is not completely known. 
However, findings from epidemiological studies have suggested that patients with 
diabetes mellitus who develop neuropathy, compared with those patients who do not, 
seem to have different cardiovascular function, glycaemic control, weight, rates of 
obesity, waist circumference, risk of peripheral arterial disease and triglyceride plasmid 
levels. Indeed, patients with diabetes mellitus have alterations in the peripheral and 
central pain pathways; other mechanistic contributors include blood glucose instability, 
increased peripheral nerve epineural blood flow, microcirculation of the skin of the foot, 
altered intraepidermal nerve fibre density, increased thalamic vascularity and autonomic 
dysfunction. Furthermore, methylglyoxal (a by-product of glycolysis) plasma levels are 
increased in patients with diabetes mellitus owing to excessive glycolysis and decreased 
degradation by the glyoxalase system197. This metabolite activates peripheral nerves by 
changing the function of Nav1.7 and Nav1.8 voltage-gated sodium channnels197 and 
might, therefore, have a role in painful neuropathy. Studies in animals have shown that 
methylglyoxal slows nerve conduction, heightens calcitonin gene-related peptide release 
from nerves and leads to thermal and mechanical hyperalgesia197. Notably, 
methylglyoxal-dependent modifications of sodium channels induce diabetes-associated 
hyperalgesia that is not simply due to changes in peripheral fibres197.
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Box 4
Challenges in translating animal studies to therapeutic pharmacological 
targets in humans
Translating knowledge from preclinical observations in animal models to new targeted 
drug therapies in the clinic has been challenging. The differences between animal 
behavioural tests and human neuropathic pain features, lack of long-term efficacy data in 
animal models and the homogeneity of animal genetic strains might contribute to these 
challenges. Nonetheless, a substantial part of our knowledge of neuropathic pain 
mechanisms is derived from animal studies. Animal models of neuropathic pain use 
surgical lesions of the spinal cord, cranial and peripheral sensory nerves, such as ligation, 
constriction or transection of parts or branches of nerves198. These animal models exhibit 
hypersensitivity to external stimuli, commonly to mechanical stimuli as assessed with 
von Frey hairs (for measuring the tactile sensitivity), but may also include 
hypersensitivity to thermal stimuli (especially cold). Higher-level outcome measurements 
that are suggestive of reward from pain relief and reflective of the spontaneous pain 
experienced by patients have recently been introduced in the array of animal models of 
neuropathic pain199. Models of diabetic neuropathy have also been affected by the ill 
health of the animals, but this aspect is starting to be addressed in the most recent 
studies38.
Notably, basic research findings have often led to the development of specific therapeutic 
targets. For example, the altered function of the sodium channels within the damaged 
peripheral nerves provides insights into the use of topical voltage-gated sodium channel 
blockade (such as lidocaine107 and carbamazepine186) for neuropathic pain. Moreover, 
the assumption of abnormal sodium channel activity has led to the use of oxcarbazepine, 
which has been shown to be more effective in patients with the ‘irritable nociceptor’ 
phenotype186. Drugs such as gabapentin and pregabalin200 (see Management) target the 
α2δ subunit of the voltage-dependent calcium channels that are overexpressed in patients 
with neuropathic pain. When given intrathecally, gabapentin inhibited hypersensitivity in 
animal models201 but has failed to show positive results in humans202.
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Figure 1. The peripheral and central changes induced by nerve injury or peripheral neuropathy
Preclinical animal studies have shown that damage to all sensory peripheral fibres (namely, 
Aβ, Aδ and C fibres; BOX 1) alters transduction and transmission due to altered ion channel 
function. These alterations affect spinal cord activity, leading to an excess of excitation 
coupled with a loss of inhibition. In the ascending afferent pathways, the sensory 
components of pain are via the spinothalamic pathway to the ventrobasal medial and lateral 
areas (1), which then project to the somatosensory cortex allowing for the location and 
intensity of pain to be perceived (2). The spinal cord also has spinoreticular projections and 
the dorsal column pathway to the cuneate nucleus and nucleus gracilis (3). Other limbic 
projections relay in the parabrachial nucleus (4) before contacting the hypothalamus and 
amygdala, where central autonomic function, fear and «anxiety are altered (5). Descending 
efferent pathways from the amygdala and hypothalamus (6) drive the periaqueductal grey, 
the locus coeruleus, A5 and A7 nuclei and the rostroventral medial medulla. These 
brainstem areas then project to the spinal cord through descending noradrenaline (inhibition 
via α2 adrenoceptors), and, in neuropathy, there is a loss of this control and increased 
serotonin descending excitation via 5-HT3 receptors (7). The changes induced by peripheral 
neuropathy on peripheral and central functions are shown. Adapted with permission from 
REF. 38, Mechanisms and management of diabetic painful distal symmetrical 
polyneuropathy, American Diabetes Association, 2013. Copyright and all rights reserved. 
Material from this publication has been used with the permission of American Diabetes 
Association.
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Figure 2. Neuroanatomical distribution of pain symptoms and sensory signs in neuropathic pain 
conditions
Distribution of pain and sensory signs in common peripheral and central neuropathic pain 
conditions. *Can sometimes be associated with central neuropathic pain. ‡Can sometimes be 
associated with peripheral neuropathic pain.
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Figure 3. Schematic representation of the conditioned pain modulation
The conditioned pain modulation (CPM) paradigm is used in the research setting to assess 
the change of perceived pain by a test stimulus under the influence of a conditioning 
stimulus203. A test stimulus can be a thermal contact stimulation (1), mechanical pressure 
(2), an electrical stimulus (3) — for each, either pain threshold or suprathreshold magnitude 
estimation can be used — or nociceptive withdrawal reflex (4). A typical conditioning 
stimulus consists of thermal contact stimulation (5), or immersion in a cold (6) or hot (7) 
water bath. Other modalities can be used as well. During a CPM assessment, a test stimulus 
is given first, then the conditioning stimulus is given, and the test is repeated during or 
immediately after the conditioning.
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Figure 4. Diagnosing neuropathic pain, a
The flowchart summarizes the clinical steps in diagnosing neuropathic pain, which involves 
taking the patient history, examining the patient and following up with confirmatory tests. If 
the answer is ‘no’ after examination, the patient might still have probable neuropathic pain. 
In such cases, confirmation tests could be performed if sensory abnormalities are not found; 
for example, in some hereditary conditions, sensory abnormalities are not found at the 
moment of examination. *History of a neurological lesion or disease relevant to the 
occurrence of neuropathic pain. ‡The patient's pain distribution reflects the suspected lesion 
or disease. §Signs of sensory loss are generally required. However, touch-evoked or thermal 
allodynia might be the only finding at bedside examination. ||‘Definite’ neuropathic pain 
refers to a pain that is compatible with the features of neuropathic pain and confirmatory 
tests are consistent with the location and nature of the lesion or disease, although this may 
not imply any causality. b | The confirmatory tests for neuropathic pain include quantitative 
sensory testing (in which the patient provides a subjective report on a precise and 
reproducible stimulus), blink reflex testing (whereby the trigeminal afferent system is 
investigated by recording the R1 and R2 reflex responses recorded from the orbicularis oculi 
muscle) and nerve conduction study (which assesses non-nociceptive fibre function of the 
peripheral nerves). Somatosensory-evoked potentials (N9 is generated by the brachial plexus 
and N20 by the somatosensory cortex) and laser-evoked potentials (LEPs), both recorded 
from the scalp, are neurophysiological tools that investigate large and small afferent fibre 
function. The N1 LEP wave is a lateralized component and generated by the secondary 
somatosensory cortex, and the negative-positive complex of LEP (N2-P2) is a vertex 
recorded potential, which is generated by the insular cortex bilaterally and the cingulate 
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cortex204. A skin biopsy enables the quantification of the intraepidermal nerve fibres, which 
provides a measure of small-fibre loss77. Finally, corneal confocal microscopy assesses 
corneal innervation, which consists of small nerve fibres. In most patients with neuropathic 
pain, standard neurophysiological testing, such as blink reflex, nerve conduction study and 
somatosensory-evoked potentials, is sufficient for showing the damage of the somatosensory 
system. However, in patients with selective damage of the nociceptive system, a nociceptive-
specific tool, such as LEPs, skin biopsy or corneal confocal microscopy, is needed. 
Typically, tests are performed in the sequence of increasing invasiveness; that is, quantitative 
sensory testing, blink reflex, nerve conduction study, somatosensory-evoked potentials, 
LEPs, skin biopsy and corneal confocal microscopy. SNAP, sensory nerve action potential. 
Adapted with permission from REF 77, Macmillan Publishers Limited. The corneal 
innervation image in part b (left panel) is reproduced with permission from REF 86, 
Elsevier.
Colloca et al. Page 41
Nat Rev Dis Primers. Author manuscript; available in PMC 2017 March 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. Subgrouping patients with peripheral neuropathic pain based on sensory signs
On the basis of two well-established testing (n = 902) (part a) and control (n=233) (part b) 
data sets69, three categories of patient phenotypes for neuropathic pain have been proposed: 
sensory loss, thermal hyperalgesia and mechanical hyperalgesia. Positive scores indicate 
positive sensory signs (hyperalgesia), and negative scores indicate negative sensory signs 
(hypoaesthesia or hypoalgesia). Values observed in those with neuropathic pain are 
significantly different from those of healthy participants when the 95% CI does not cross the 
zero line, which defines the average of data from normal subjects. Insets (right) show the 
numerical rating scale (NRS; 0–10) values for dynamic mechanical allodynia (DMA) on a 
logarithmic scale and the frequency of paradoxical heat sensation (PHS) on a scale of 0–3. 
These findings indicate that patients with neuropathic pain have different expression patterns 
of sensory signs. These subgroup results suggest that different mechanisms of pain 
generation are involved in the pain condition. Furthermore, the first clinical trial to show 
phenotype stratification based on these sensory profiles has predictive power for treatment 
response186. Error bars are the graphical representation of the variability of the data present 
in the database. CDT, cold detection threshold; CPT, cold pain threshold; HPT, heat pain 
threshold; MDT, mechanical detection threshold; MPS, mechanical pain sensitivity; MPT, 
mechanical pain threshold; PPT, pressure pain threshold; QST, quantitative sensory test; 
TSL, thermal sensory limen; VDT, vibration detection threshold; WDT, warm detection 
threshold; WUR, wind-up ratio. Reproduced with permission from REF 70, Baron, R. et al., 
Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory 
profiles, Pain, 158, 2, 261–272, http://journals.lww.com/pain/Fulltext/2017/02000/
Peripheral_neuropathic_pain___a_mechanism_related.10.aspx
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Figure 6. Example interventional treatments for neuropathic pain. a
Spinal cord stimulation traditionally applies a monophasic square-wave pulse (at a frequency 
in the 30–100 Hz range) that results in paraesthesia in the painful region. b | Cortical 
stimulation involves the stimulation of the pre-central motor cortex below the motor 
threshold using either invasive epidural or transcranial non-invasive techniques (such as 
repetitive transcranial magnetic stimulation (TMS) and transcranial direct current 
stimulation). c | Deep brain stimulation uses high-frequency chronic intracranial stimulation 
of the internal capsule, various nuclei in the sensory thalamus, periaqueductal and 
periventricular grey, motor cortex, septum, nucleus accumbens, posterior hypothalamus and 
anterior cingulate cortex as potential brain targets for pain control. d | Intrathecal treatments 
provide a targeted drug delivery option in patients with severe and otherwise refractory 
chronic pain. The pumps can be refilled through an opening at the skin surface.
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Table 1
Available pharmacotherapy for neuropathic pain
Drug Mechanisms of action NNT* (range) Adverse effects Precautions and contraindications
Tricyclic antidepressants
Nortriptyline, 
desipramine, 
amitriptyline, 
clomipramine and 
imipramine
Monoamine reuptake 
inhibition, sodium channel 
blockade and anticholinergic 
effects
3.6 (3–4.4) Somnolence, 
anticholinergic 
effects and weight 
gain
• Cardiac disease, glaucoma, prostatic 
adenoma and seizure
• High doses should be avoided in 
adults >65 years of age and in those 
with amyloidosis
Serotonin-noradrenaline reuptake inhibitors
Duloxetine Serotonin and noradrenaline 
reuptake inhibition
6.4 (5.2–8.2) Nausea, 
abdominal pain 
and constipation
• Hepatic disorder and hypertension
• Use of tramadol
Venlafaxine Serotonin and noradrenaline 
reuptake inhibition
6.4 (5.2–8.2) Nausea and 
hypertension at 
high doses
• Cardiac disease and hypertension
• Use of tramadol
Calcium channel α2δ ligands
Gabapentin, extended-
released gabapentin and 
enacarbil, and pregabalin
Act on the α2δ subunit of 
voltage-gated calcium 
channels, which decrease 
central sensitization
• 6.3 (5–8.4 for 
gabapentin)
• 8.3 (6.2–13 
for extended-
released 
gabapentin and 
enacarbil)
• 7.7 (6.5–9.4 
for pregabalin)
Sedation, 
dizziness, 
peripheral oedema 
and weight gain
Reduce dose in patients with renal 
insufficiency
Topical lidocaine
Lidocaine 5% plaster Sodium channel blockade Not reported Local erythema, 
itching and rash
None
Capsaicin high-
concentration patch (8%)
Transient receptor potential 
cation channel subfamily V 
member 1 agonist
10.6 (7.4–19) Pain, erythema, 
itching and rare 
cases of high 
blood pressure 
(initial increase in 
pain)
No overall impairment of sensory 
evaluation after repeated applications 
and caution should be taken in 
progressive neuropathy
Opioids
Tramadol μ-Receptor agonist and 
monoamine reuptake 
inhibition
4.7 (3.6–6.7) Nausea, vomiting, 
constipation, 
dizziness and 
somnolence
History of substance abuse, suicide risk 
and use of antidepressant in elderly 
patients
Morphine and oxycodone μ-Opioid receptor agonists; 
oxycodone might also cause 
κ-opioid receptor 
antagonism
4.3 (3.4–5.8) Nausea, vomiting, 
constipation, 
dizziness and 
somnolence
History of substance abuse, suicide risk 
and risk of misuse in the long term
Neurotoxin
Botulinum toxin A Acetylcholine release 
inhibitor and 
neuromuscular-blocking 
1.9 (1.5–2.4) Pain at injection 
site
Known hypersensitivity and infection of 
the painful area
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Drug Mechanisms of action NNT* (range) Adverse effects Precautions and contraindications
agent; potential effects on 
mechanotransduction and 
central effects in 
neuropathic pain
*Number needed to treat (NNT) for 50% pain relief represents the number of patients necessary to treat to obtain one responder more than the 
comparison treatment, typically placebo101.
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